Recruiting Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas NCT06202066 Conditions Adenoma, Adenoma, Islet Cell, Digestive System Diseases, +13 more Locations Roswell Park Cancer Institute — Buffalo, New York, United States View Trial Details
Active, Not Recruiting Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors NCT03950609 Conditions Advanced Carcinoid Tumor, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Neuroendocrine Neoplasm, +16 more Locations M D Anderson Cancer Center — Houston, Texas, United States View Trial Details
